Ono Pharmaceutical and Biofocus have signed an agreement focused on discovering novel targets in the field of auto-immune disease using Biofocus's Silenceselect target discovery platform.
Under the agreement, Biofocus will receive research funding and success payments based on the progress of the collaboration.
Biofocus will utilise its Silenceselect target discovery platform to deliver validated targets for Ono's immunology programmes.
Ono aims to find modulators for these targets and generate novel and innovative drug candidates.
